Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. The company is making enzymes for companies operating in the following industries: pharmaceuticals, biotherapeutics, food & beverage, and molecular diagnostics.
On June 20, 2019 Codexis completed a growth funding round with $50 million in funding from Casdin Capital. The funding is through a private placement of Codexis common stock, and will be used to fund strategic growth initiatives for the companies activity in the synthetic biology market. The president and CEo of Codexis made the following public statement regarding Casdin Capital's investment:
The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets. Casdin has long recognized our technology and leadership capability and, with their latest investment, we have significant financial flexibility to capitalize on a variety of growth opportunities.
David J. Galgoczy
David McCaman, CPA
Dayna H. Johnson
Senior Vice President, CFO
Senior Vice President of R&D
Kamrin Mac Knight
Lana Spencer, PG, CHMM, QISP
Corporate and Strategic Development
Documentaries, videos and podcasts